Fintel reports that on November 14, 2024, Citigroup initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

Gilead Sciences Inc. closed $1.29 short of its 52-week high ($98.32), which the company reached on November 7th. Supported by world-class markets data from Dow Jones and FactSet, and partnering ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

On Thursday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $97.9 which represents a slight increase of $6.21 or 6.77% from the prior close of $91.69. The stock opened at ...

Gilead Sciences ( (GILD) ) has released its Q3 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.

2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. SANTA MONICA, Calif., November 05, 2024--Kite, a Gilead Company (Nasdaq: GILD), will share ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. “Gilead’s third quarter results are the strongest o ...